Related Experiment Videos
Erythromycin A oxime 11,12-carbonate and its oxime ethers
E G Brain1, A K Forrest, E Hunt
1Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Surrey, UK.
The Journal of Antibiotics
|December 1, 1989
Summary
Erythromycin A oxime carbonate and its derivatives demonstrate potent antibacterial activity against Gram-positive and Gram-negative bacteria. Some compounds exhibit superior efficacy compared to existing erythromycin A derivatives.
Area of Science:
- Medicinal Chemistry
- Microbiology
- Organic Synthesis
Background:
- Erythromycin A is a crucial macrolide antibiotic.
- Modifications of erythromycin A aim to enhance its antibacterial spectrum and potency.
- Carbonate and oxime derivatives are explored for improved therapeutic properties.
Purpose of the Study:
- To synthesize novel erythromycin A oxime 11,12-carbonate derivatives.
- To evaluate and compare the in vitro antibacterial activities of these new compounds.
- To assess their efficacy against Gram-positive and Gram-negative bacteria.
Main Methods:
- Chemical synthesis of erythromycin A oxime 11,12-carbonate (5a) and its oxime ethers (5b-5p).
- Comparative in vitro antibacterial assays.
- Testing against a panel of Gram-positive and Gram-negative microorganisms.
Main Results:
- The synthesized oxime 5a and several oxime ether derivatives displayed significant antibacterial activity.
- These compounds were effective against both Gram-positive and more permeable Gram-negative bacteria.
- Some derivatives showed enhanced activity compared to erythromycin A 11,12-carbonate (2).
Conclusions:
- Erythromycin A oxime 11,12-carbonate derivatives represent a promising class of antibacterial agents.
- These novel compounds offer potential as alternatives or improvements over existing macrolide antibiotics.
- Further investigation into their mechanism of action and in vivo efficacy is warranted.